Stocks and Investing
Stocks and Investing
Fri, September 27, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Yigal Nochomovitz Downgraded (SMMT) to Hold and Increased Target to $23 on, Sep 27th, 2024
Yigal Nochomovitz of Citigroup, Downgraded "Summit Therapeutics Inc." (SMMT) to Hold and Increased Target from $19 to $23 on, Sep 27th, 2024.
Yigal has made no other calls on SMMT in the last 4 months.
There are 2 other peers that have a rating on SMMT. Out of the 2 peers that are also analyzing SMMT, 0 agree with Yigal's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Yigal
- Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $40 on, Wednesday, September 25th, 2024
- Mitchell Kapoor of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $45 on, Tuesday, September 17th, 2024
Contributing Sources